PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorFederation Francophone de Cancerologie Digestive
About this trial
The goal of this trial is to determine whether the combination of CISGEM and Rilvegostomig during the perioperative period works to improve outcomes of patient undergoing surgery of high-risk of intrahepatic cholangiocarcinoma
Eligibility criteria
Qualifiers
Age ≥ 18 years
WHO Performance Status 0-1
Body weight > 30kg
Histo/cytologically proven intrahepatic cholangiocarcinoma.
Disqualifiers
Existence of metastases or distant lymph node involvement considered as metastatic
Locally advanced disease considered as definitively non resectable
Cirrhosis with Child Pugh ≥ B7
Any history of liver decompensation: hepatic encephalopathy, presence of ascites
Trial design
Treatments tested in this trial
- CISGEM + Rilvegostomig
Treatment groups
49 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov